Health Care · Orthopedic, Prosthetic & Surgical Appliances & Supplies

ZBH Zimmer Biomet SEC Filings & Insider Trading Activity 2026

company
CIK 1136869126 filings
S&P 500

ZBH at a glance

Zimmer Biomet (ZBH, SEC CIK 1136869) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Zimmer Biomet (ZBH) reported revenue of $8.2 billion (up 7.2% from FY2024) and net income of $705.1 million. Diluted EPS was $3.55.
  • As of September 30, 2026, 47 institutional investment managers tracked by SignalX reported holding Zimmer Biomet (ZBH) shares worth $6.0 billion in 13F-HR filings.
  • In the last 90 days, ZBH insiders reported 0 open-market purchases ($0) and 2 open-market sales ($824K) on Form 4, a net sale of $824K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$8.2B
+7.2% vs prior year
Insiders · 90 days
0 buys · 2 sells
Net −$824K
13F holders
47 funds
$6.0B · +1 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 1.01 · Item 2.03

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Adoption of Zimmer Biomet Code of Ethics for CEO and senior financial officers, publicly accessible online
  • Implementation of insider trading policy for directors, senior management, and employees, included as exhibit in 10-K
  • Corporate governance and executive compensation details incorporated by reference from 2026 Proxy Statement
  • No new products, services, or strategic shifts disclosed within this filing's Business section

Risk Factors

  • Cybersecurity risk oversight by Audit Committee with immediate escalation of material incidents to board
  • Potential operational disruption from evolving global cybersecurity threats monitored by specialized global security team
  • Cybersecurity incident review managed by cross-functional subcommittee including info security, legal, accounting, internal audit
  • Leadership by VP CISO with 30+ years IT security experience driving cybersecurity program and reporting to Audit Committee
  • Security operations team includes advanced degree and certified professionals supporting ongoing cybersecurity enhancements

Management Discussion & Analysis

  • Revenue $8,231.5M in 2025, up 7.2% YoY from $7,678.6M, driven by Paragon 28 acquisition (+2.5%), market growth, and currency effects (+0.8%)
  • Operating margin 13.3% in 2025 vs 16.7% in 2024, decline due to inventory charges (~$170M), acquisition/integration costs, tariffs, and higher compensation
  • Best segment Americas: operating profit $2,645.7M (51.4% of sales), worst Asia Pacific: operating profit $446.0M (35.5% margin), both margins down YoY
  • Operating cash flow $1,697.1M up from $1,499.4M; investing cash outflow $1,975.7M mainly for acquisitions ($1,393.2M); financing cash inflow $326.0M with $487M share buybacks and dividend payments of $0.24/share quarterly
  • 2026 outlook: net sales growth 2.5%-4.5%, operating profit to increase YoY; risks include inflation, interest expense, effective tax rate increase, and go-to-market execution changes

AI summary of the ZBH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to 2025 Form 10-K risk factors disclosed
  • Carried-forward risks could materially affect business, financial condition and results of operations
  • Additional unknown or currently immaterial risks could become materially adverse

Management Discussion & Analysis

  • Quarterly revenue $2,062.9M, up 3.1% from $2,001.4M YoY
  • Operating margin 14.9% vs 17.6% YoY, net earnings $191.6M vs $230.9M
  • Best category Technology & Data, Bone Cement and Surgical, $180.6M, up 11.9%; worst Knees, $767.5M, down 3.1%
  • Nine-month operating cash flow $1,367.2M vs $1,179.7M; share repurchases $579.3M
  • 2026 sales-growth guidance 4.4% to 4.9%; headwinds from pricing pressure, inflation and commercial investments

AI summary of the ZBH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • $1.0B total debt issuance completed November 12, 2026, expanding Zimmer Biomet’s financing capacity
  • €500.0M notes at 4.375% due 2033, creating euro-denominated interest and refinancing exposure

Item 2.03: Creation of a Direct Financial Obligation

  • New EUR Notes carry 4.375% annual interest and mature November 12, 2033
  • New USD Notes carry 5.850% semiannual interest and mature November 12, 2036
Filed Nov 4, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 net sales $2.063B, up 3.1% reported and 3.7% constant currency, signaling improving underlying demand
  • Adjusted diluted EPS $1.90, flat year over year, while GAAP diluted EPS fell 13.8% to $1.00

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results for quarter ended September 30, 2026 released November 4, 2026
  • Detailed financial results and management commentary available in Exhibit 99.1
Filed Sep 8, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Group President Kevin Thornal departing September 30, 2026 following restructuring of his position
  • Leadership transition affects Global Businesses and Americas operations

Item EX-99.1: Item EX-99.1

  • Effective October 1, Gary Campbell becomes President, Americas, leading commercial strategy across the United States, Canada and Latin America
  • Brian Hatcher expands to global portfolio leadership, adding Knees and Hips to Recon, S.E.T., CMFT, Neuro and Biosurgery

Item 7.01: Regulation FD Disclosure

  • Press release issued September 8, 2026 regarding the Item 5.02 officer or director matters
  • Exhibit 99.1 contains the substantive announcement relevant to investors

AI summaries of ZBH 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ZBH

Don't miss the next ZBH filing

  • Alerts as it files. A push when ZBH files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ZBH, by share count.
  • Ask anything. An AI agent that reads every ZBH filing and answers with sources.

ZBH alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Campbell Gary CraigMOct 1, 2026-
Campbell Gary CraigMOct 1, 2026-
Campbell Gary CraigMOct 1, 2026-
Campbell Gary CraigMOct 1, 2026-
Campbell Gary CraigFOct 1, 2026$88.42
Campbell Gary CraigFOct 1, 2026$88.42
HIGGINS ARTHUR JASep 30, 2026-
Hilado Maria TeresaASep 30, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$7.7B$8.2B
Operating Income-$1.3B$1.1B
Net Income$1.0B$903.8M$705.1M
Op. Margin-16.7%13.3%
Net Margin-11.8%8.6%
Balance Sheet
Total Assets$21.5B$21.4B$23.1B
Equity-$12.5B$12.7B
ROE-7.2%5.6%
Per Share
EPS$4.88$4.43$3.55
Cash Flow
Operating CF-$1.5B$1.7B
CapEx$291.1M$203.8M$224.5M

Source: XBRL data in Zimmer Biomet (ZBH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ZBH share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ZBH shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202647$6.05B
Q2 202646$6.34B
Q1 202643$7.08B
Q4 202542$7.36B
Q3 202549$8.82B
Q2 202542$8.18B
Q1 202545$7.00B
Q4 202440$5.65B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers

Source: 13F-HR filings on SEC EDGAR (aggregated from 354 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ZBH filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 12, 2026Analysis-
8-KNov 4, 2026Analysis-
10-QNov 4, 2026Analysis
4Oct 5, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Sep 15, 2026--
4Sep 9, 2026--
8-KSep 8, 2026Analysis-
SC 13GAug 12, 2026-
10-QAug 5, 2026Analysis
4Aug 5, 2026--
8-KAug 5, 2026Analysis-
8-KAug 5, 2026Analysis-
4Aug 4, 2026--
4Jul 2, 2026--
4Jul 2, 2026--
4Jul 2, 2026--
4Jul 2, 2026--
4Jul 2, 2026--

Related Health Care companies

All Health Care →

ZBH SEC filings: frequently asked questions

Are ZBH insiders buying or selling?

In the last 90 days, Zimmer Biomet (ZBH) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $824,028 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ZBH stock?

As of September 30, 2026, the largest Zimmer Biomet (ZBH) holders among the 13F filers tracked by SignalX were BlackRock ($1.4 billion), Vanguard Capital Management LLC ($1.1 billion), State Street Corp ($791.2 million), Vanguard Portfolio Management LLC ($723.1 million), Invesco Ltd ($366.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ZBH's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Zimmer Biomet (ZBH) reported revenue of $8.2 billion (up 7.2% from FY2024) and net income of $705.1 million. Diluted EPS was $3.55. The figures come from the XBRL data in the 10-K.

What are the main risks in ZBH's latest 10-K?

In the 10-K filed February 20, 2026, Zimmer Biomet (ZBH) flagged: Cybersecurity risk oversight by Audit Committee with immediate escalation of material incidents to board. Potential operational disruption from evolving global cybersecurity threats monitored by specialized global security team. (AI summary of the Risk Factors section.)

What did ZBH report in its latest 8-K?

Zimmer Biomet (ZBH) filed an 8-K on November 12, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation). $1.0B total debt issuance completed November 12, 2026, expanding Zimmer Biomet’s financing capacity.

What are the latest ZBH SEC filings?

Zimmer Biomet (ZBH) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on October 5, 2026.

What is ZBH's SEC CIK number?

Zimmer Biomet (ZBH)'s SEC Central Index Key (CIK) is 1136869. EDGAR lists every ZBH filing under that number.

Ask anything about ZBH

The research agent reads ZBH's filings, financials, insider trades and 13F holders, then answers with sources.